Introduction
============

Chronic heart failure (CHF) ([@b1-etm-0-0-8269]) is a group of clinical syndromes caused by changes in cardiac structure and function caused by various reasons, leading to the reduction of left ventricular filling and ejection fraction. It is the final stage of development of various cardiovascular diseases and is also the main cause of death ([@b2-etm-0-0-8269]). Heart failure (HF) refers to cardiac circulatory disorder syndrome caused by failing to fully discharge venous return volume out of the heart due to dysfunction of cardiac systolic and/or diastolic function, resulting in blood deposition in venous system and insufficient blood perfusion in arterial system. Such disorder syndrome is mainly manifested as pulmonary congestion and vena cava congestion ([@b3-etm-0-0-8269]). HF is not an independent disease, but the final stage of the development of heart diseases, most of which begin with left HF ([@b4-etm-0-0-8269]). Therefore, it is of great significance to find the disease in time and control and treat it to remission.

Studies have shown that patients with CHF have pathophysiological changes such as myocardial electrical remodeling, which can be characterized by cardiac rhythm. Therefore, electrocardiogram (ECG) of patients with CHF may have special ECG manifestations ([@b5-etm-0-0-8269]). Some studies have shown that myocardial interstitial collagen deposition in patients with CHF and arrhythmia can affect the maintenance of ventricular structure and cardiac function ([@b6-etm-0-0-8269]). Previous studies have shown that type III procollagen amino-terminal peptide (PIIINP) is a metabolic product during myocardial collagen synthesis, which can better reflect the index of collagen fiber formation *in vivo* ([@b7-etm-0-0-8269]). Brain natriuretic peptide (BNP) is mainly synthesized in ventricular myocytes and secreted by the left ventricle. It flows back into the small vein to the interventricular septum vein and enters the circulation through the coronary sinus ([@b8-etm-0-0-8269],[@b9-etm-0-0-8269]). Ventricular wall tension, pressure overload, myocardial ischemia, necrosis and injury can stimulate the synthesis and release of BNP. BNP is a sensitive index reflecting ventricular function and load, and is widely used in evaluating cardiac function ([@b10-etm-0-0-8269]).

Therefore, the purpose of this investigation was to monitor the condition of patients with CHF and arrhythmia by observing the changes of ECG indexes, and to study the relationship between ECG indexes and serum PIIINP and BNP.

Patients and methods
====================

### General information

From December 2017 to December 2018, 101 patients with HF were collected. Among them, 48 patients with HF and slow arrhythmia were in group A, including 31 males and 16 females, with an average age of 57.6±3.7 years and a course of disease of 1.75±0.07 years, while 53 cases of those with HF and non-slow arrhythmia were in group B, including 33 males and 20 females, with an average age of 59.2±4.1 years and course of disease of 1.89±0.09 years. Further data are shown in [Table I](#tI-etm-0-0-8269){ref-type="table"}. There was no statistical significance between the two groups.

The study was approved by the Ethics Committee of Yantai Yuhuangding Hospital (Yantai, China). Signed informed consents were obtained from the patients and/or the guardians.

### Exclusion and inclusion criteria

Inclusion criteria ([@b1-etm-0-0-8269]) were CHF B with arrhythmia confirmed by ECG and echocardiography, and left ventricular ejection fraction ≤40% ([@b11-etm-0-0-8269]). Exclusion criteria were: i) thyroid and lung diseases; ii) sick sinus syndrome patients; iii) those who did not wish to be included in this study.

Methods and detection indexes
-----------------------------

### Specimen collection

Altogether 2--3 ml venous blood of all the selected patients were taken on admission, and the next day on an empty stomach, and the relevant biochemical indexes were checked.

### BNP test

Fasting venous blood of patients was collected, 15% EDTA was added into anticoagulation test tube, and centrifuged at 1,509.3 × g at 4°C for 10 min with an effective centrifugal radius of 15 cm. The blood was detected by chemiluminescence using Pulangpuzs-300 series automatic biochemical analyzer (Hitachi 7180 type).

### PIIINP detection

Fasting venous blood of patients was collected, 15% EDTA was added to anticoagulation test tube, centrifuged at 1,509.3 × g at 4°C for 10 min with an effective centrifugal radius of 15 cm, and the separated serum was stored in a low temperature refrigerator at −20°C for later use. Balanced radioimmunoassay was used for determination, and radioimmunoassay reagent was provided by Biotechnology Center of Hunan Pharmaceutical Research Institute.

### Detection of ECG index changes in the two groups

After admission, the ECG changes of the two groups were observed, including heart rate, Q-T interval, P-R interval and QRS wave group, and recorded.

### Correlation between serum PIIINP, BNP and NYHA classification of cardiac function ([@b12-etm-0-0-8269])

Patients with different NYHA classification of cardiac function were grouped, and the expression levels of PIIINP and BNP in the patients were detected. Through Pearson correlation factor analysis, the correlation between serum PIIINP, BNP and NYHA classification of cardiac function was analyzed.

### Correlation between ECG indexes and PIIINP and BNP

Through Pearson correlation factor analysis, the correlation between ECG indexes and PIIINP and BNP expression level was analyzed.

### ROC curve analysis ([@b13-etm-0-0-8269])

The receiver operating characteristic curve (ROC) was used to analyze whether serum PIIINP and BNP had diagnostic value in CHF with arrhythmia.

### Statistical methods

This study used SPSS18.0 software (Bizinsight (Beijing) Information Technology Co., Ltd.) to carry out statistical analysis on the data. GraphPad Prism 6 software was used to draw the illustrations in this study. Chi-square test was used to compare the counting data, and mean ± standard deviation to express the measurement data. t-test was emplyed to analyze the two groups, and variance analysis to compare the multiple groups, and Pearson correlation analysis was used to analyze the relationship between variables. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Levels of serum PIIINP and BNP of patients in the two groups

The content of serum PIIINP and BNP of patients in the two groups showed that the serum PIIINP and BNP in group A were significantly higher than those in group B (P\<0.05). The levels of PIIINP and BNP in serum of NYHA patients with different cardiac functions, and those in serum of patients with class III were significantly higher than those of group II (P\<0.05), while significantly lower than those of group IV (P\<0.05) ([Fig. 1](#f1-etm-0-0-8269){ref-type="fig"}).

### Changes of ECG indexes in the two groups

The ECG indexes such as heart rate, Q-T interval, P-R interval and QRS wave of patients in the two groups were examined. The results revealed that the heart rate and Q-T interval of group A were significantly higher than those of group B (P\<0.05), and the P-R interval and QES wave in group A were significantly lower than those in group B (P\<0.05) ([Fig. 2](#f2-etm-0-0-8269){ref-type="fig"}).

### Correlation analysis

Pearson correlation analysis indicated that BNP was correlated with Hr, G-T, P-R and QRS, positively correlated with Hr and G-T (r=0.7749, r=0.6743), and was negatively correlated with P-R and QRS (r=−0.6684, r=−0.6811). PIIINP was positively correlated with Hr, G-T, P-R, and QRS (r=0.5509, r=0.5635), and was negatively correlated with P-R and QRS (r=−0.5730, r=−0.7707). BNP, PIIINP and NYHA had positive correlation (r=0.5804, r=0.5813) ([Figs. 3](#f3-etm-0-0-8269){ref-type="fig"} and [4](#f4-etm-0-0-8269){ref-type="fig"}).

### ROC curve analysis

ROC curve analysis represented that ACU of BNP in diagnosing patients with CHF was 0.8829, the sensitivity was 69.51%, and the specificity was 81.61%; AUC of PIIINP in diagnosing patients with CHF was 0.6340, the sensitivity was 73.64%, and the specificity was 52.71%. ([Table II](#tII-etm-0-0-8269){ref-type="table"} and [Fig. 5](#f5-etm-0-0-8269){ref-type="fig"}).

Discussion
==========

HF usually refers to the deterioration of myocardial contractility, which leads to insufficient output to meet the needs of collective metabolism, affecting the perfusion of organs and tissues, and is often accompanied by passive hemorrhage of systemic circulation and pulmonary circulation. CHF is mainly caused by physiological changes, and the pathogenesis of ventricular arrhythmia is mainly abnormal depolarization activity, increased self-discipline and conduction reversion. When CHF progresses to hypofilling function or ventricular pumping, or ventricular tachycardia and ventricular arrhythmia is prematurely triggered, leading to arrhythmia, and in serious cases, ventricular fibrillation will even lead to death ([@b14-etm-0-0-8269]). Antiarrhythmic drugs are commonly used in clinical treatment of CHF with ventricular arrhythmia, which can effectively improve clinical symptoms and control arrhythmia, but the treatment effect is slow.

Collagen in myocardial interstitium is mostly type III collagen. Collagen, like other proteins, is transcribed into mRNA in cells via DNA and then translated and expressed as procollagen α peptide. The amino end and carboxyl end of procollagen each have a non-collagen terminal peptide. After hydroxylation, procollagen molecules form a triple helix, which is secreted by cardiac fibroblasts after saccharification ([@b15-etm-0-0-8269]). Therefore, PIIINP can accurately reflect the active process of collagen synthesis in cardiac tissue. BNP is mainly produced in ventricles, and the release of BNP increases with the increase of ventricular wall tension and load in HF. At present, many studies have proved that BNP plays an important role in the diagnosis and risk degree of HF ([@b16-etm-0-0-8269],[@b17-etm-0-0-8269]). It is also believed that BNP can be used as the mortality indicator of patients with HF in hospital and at 6 months and one year after discharge ([@b18-etm-0-0-8269]), but there is a lack of research on arrhythmia ([@b19-etm-0-0-8269]). This study found that the concentration of BNP in plasma of ventricular arrhythmia group was significantly higher than that of non-ventricular arrhythmia group, which might be due to the increase of cardiac load caused by the change of hemodynamics affected by ventricular arrhythmia.

ECG is a technique for recording changes in cardiac electrical activity using an electrocardiograph. It is non-invasive, convenient and inexpensive. It is the main detection method for evaluating HF. This study revealed that common ECG indicators were correlated with BNP and PIIINP proteins, which suggested that BNP and PIIINP levels could be predicted. However, ROC curve analysis of BNP and PIIINP in this study indicated that BNP and PIIINP had diagnostic value for CHF, and could predict it in advance in combination with ECG indexes.

In conclusion, ECG indicators were correlated with BNP and PIIINP, and they showed diagnostic value for CHF. Using the indexes to predict BNP and PIIINP levels was conducive to the diagnosis of CHF.
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![Changes of ECG indexes in the two groups. (A) ECG Hr in group A was significantly higher than that in group B. (B) ECG Q-T in group A was significantly higher than that in group B. (C) ECG P-R in group A was significantly lower than that in group B. (D) ECG QRS in group A was significantly lower than that in group B. \*P\<0.05. ECG, electrocardiogram.](etm-19-01-0591-g01){#f2-etm-0-0-8269}

![Correlation analysis of BNP and PIIINP with Hr, G-T, P-R and QRS (A) BNP had a positive correlation with Hr (r=0.7749). (B) BNP had a positive correlation with G-T (r=0.6743). (C) BNP was negatively correlated with P-R (r=−0.6684). (D) BNP was negatively correlated with QRS (r=−0.6811). (E) PIIINP had a positive correlation with Hr (r=0.5509). (F) PIIINP had a positive correlation with G-T (r=0.5635). (G) PIIINP had a negative correlation with P-R (r=−0.5730). (H) PIIINP had a negative correlation with QRS (r=−0.7707). The correlation analysis yielded significant results (P\<0.05). BNP, brain natriuretic peptide.](etm-19-01-0591-g02){#f3-etm-0-0-8269}

![Correlation analysis of BNP, PIIINP and NYHA. (A) BNP had positive correlation with NYHA (r=0.5804). (B) PIIINP had a positive correlation with NYHA (r=0.5813). The correlation analysis yielded significant results (P\<0.05). BNP, brain natriuretic peptide.](etm-19-01-0591-g03){#f4-etm-0-0-8269}

![ROC curve analysis. (A) ACU of BNP in diagnosing patients with CHF was 0.8829, the sensitivity was 69.51% and the specificity was 81.61%. (B) AUC of PIIINP in diagnosing patients with CHF was 0.6340, the sensitivity was 73.64%, and the specificity was 52.71%. BNP, brain natriuretic peptide; CHF, chronic heart failure.](etm-19-01-0591-g04){#f5-etm-0-0-8269}

###### 

General data.

  Factor                    Group A (n=48)   Group B (n=53)   χ^2^/t   P-value
  ------------------------- ---------------- ---------------- -------- ---------
  Sex                                                         1.958    0.1439
    Male                    31               33                        
    Female                  16               20                        
  Age                       57.6±3.7         59.2±4.1         1.743    0.814
  Course of disease         1.75±0.07        1.89±0.09        0.5912   0.3541
  Coronary heart disease    23               24               1.740    0.4583
  Hypertension              13               15               1.348    0.3674
  Rheumatic heart disease     8                5              1.181    0.4931
  Dilated cardiomyopathy      4                9              1.331    0.2405
  NYHA                                                                 
    Class II                14               16               0.4710   0.7813
    Class III               25               27               0.5188   0.5960
    Class IV                  9              10               0.001    0.9995
  Lown class III            24               24               2.782    0.5949
  Lown class IV             17               18               7.509    0.0234
  Lown class V                7              11               0.1053   0.9487

###### 

ROC curve analysis.

  Indicators   AUC      SE        95% CI           P-value
  ------------ -------- --------- ---------------- ---------
  BNP          0.8829   0.03548   0.8133--0.9524   \<0.001
  PIIINP       0.6340   0.05561   0.5250--0.7431   \<0.001

BNP, brain natriuretic peptide; PIIINP, type III procollagen amino-terminal peptide.
